ChemGenex's Omapro Faces Scaled Back Efficacy Claims After Trial Shortcomings
This article was originally published in The Pink Sheet Daily
Executive Summary
Briefing documents for the advisory committee, now delayed by snow, show that many enrollees lacked a confirmed Bcr-Abl T315I mutation.
You may also be interested in...
Teva’s Synribo: Salvage Therapy, But Not Personalized Medicine
Omacetaxine finds new life as a salvage treatment in chronic myeloid leukemia after failing to pass FDA muster for targeted therapy in patients with a particular genetic mutation. FDA allowed Teva to pool data from two open-label studies to secure approval in a third-line setting.
Pixuvri And Omapro Will Get Tight Reviews After Rescheduled Committee Meeting
Delay forced by Washington's February blizzard mean that the products won't get approved until after the March 22 ODAC panel, and Omapro seems destined to miss its PDUFA date.
Pixuvri And Omapro Will Get Tight Reviews After Rescheduled Committee Meeting
Delay forced by Washington's February blizzard mean that the products won't get approved until after the March 22 ODAC panel, and Omapro seems destined to miss its PDUFA date.